Integrase Inhibitor Compounds for HIV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection, particularly those targeting reverse transcriptase and protease, face limitations due to toxicity and the development of resistant strains, necessitating new agents that inhibit HIV replication, including those targeting integrase.
Innovation Solution
Development of specific compounds and their pharmaceutical compositions that inhibit HIV replication by targeting alternate sites in the viral life cycle, such as integrase, for use in treating HIV infections, either alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs targeting reverse transcriptase and protease are used, then HIV replication is inhibited, but toxicity and development of resistant strains occur
Solution Approach 1:
The patent segments the HIV treatment approach by introducing a new class of compounds (integrase inhibitors) that target a different enzyme in the viral replication cycle, rather than relying solely on reverse transcriptase and protease inhibitors. This diversification of therapeutic targets helps overcome resistance and reduces the harmful effects associated with prolonged use of conventional drugs.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of integrase inhibitor compounds (as shown in the various embodiments with different substituents R1-R6) to optimize their antiviral activity while minimizing toxicity and resistance development. The structural variations allow tuning of pharmacological properties to achieve better therapeutic outcomes.
2Adaptability or versatility
If new agents targeting integrase are developed, then alternate sites in the viral life cycle are inhibited, but drug complexity increases
Solution Approach 1:
The patent designs integrase inhibitor compounds with a core structural framework that can accommodate various substituents (R1-R6), allowing a single compound class to target integrase while potentially addressing multiple aspects of viral replication. This multi-functional approach enables broad adaptability against different HIV strains without proportionally increasing complexity.
Data Source
AI summary
The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.